- Volume 95, Current Issue
- Vol 28, October 2019
- Vol 27, September 2019
- Vol 26, August 2019
- Vol 25, July 2019
- Vol 24, June 2019
- Vol 23, May 2019
- Vol 22, April 2019
- Vol 21, March 2019
- Vol 20, February 2019
- Vol 19, January 2019
- Vol 18, December 2018
- Vol 17, November 2018
- Vol 16, October 2018
- Vol 15, September 2018
- Vol 14, August 2018
- Vol 13, July 2018
- Vol 12, June 2018
- Vol 11, May 2018
- Vol 10, April 2018
- Vol 9, March 2018
- Vol 8, February 2018
- Vol 7, January 2018
- Vol 6 No 12, December 2017
- Vol 6 No 11, November 2017
- Vol 6 No 10, October 2017
- Vol 6 No 9, September 2017
- Vol 6 No 8, August 2017
- Vol 6 No 7, July 2017
- Vol 6 No 6, June 2017
- Vol 6 No 5, May 2017
- Vol 6 No 4, April 2017
- Vol 6 No 3, March 2017
- Vol 6 No 2, February 2017
- Vol 6 No 1, January 2017
- Vol 5 No 12, December 2016
- Vol 5 No 11, November 2016
- Vol 5 No 10, October 2016
- Vol 5 No 9, September 2016
- Vol 5 No 8, August 2016
- Vol 5 No 7, July 2016
- Vol 5 No 6, June 2016
- Vol 5 No 5, May 2016
- Vol 5 No 4, April 2016
- Vol 5 No 3, March 2016
- Vol 5 No 2, February 2016
- Vol 5 No 1, January 2016
- Vol 4 No 12, December 2015
- Vol 4 No 11, November 2015
- Vol 4 No 10, October 2015
Cover Story Current Issue

At the turn of the 19th century, Ivan Pavlov and others established that the secretion of pancreatic juice is induced upon entry of acidic chyme into the duodenum, and that this pancreatic secretion is accelerated by infusion of hydrochloric acid (HCL) into the stomach. Pavlov hypothesized that secretion of pancreatic juice is induced via a neuronal reflex; however, pancreatic secretion prevailed in dogs following denervation of the intestinal vagal and splanchnic nerves, indicating that pancreatic secretion must be mediated by another, as yet unknown, mechanism.
Current Issue
Polyribonucleotide nucleotidyltransferase 1 participates in metabolic-associated fatty liver disease pathogenesis by affecting lipid metabolism and mitochondrial homeostasis
- Abstract
Polyribonucleotide nucleotidyltransferase 1 participates in metabolic-associated fatty liver disease pathogenesis by affecting lipid metabolism and mitochondrial homeostasis
Objective
Metabolic-associated fatty liver disease (MAFLD) represents one of the most prevalent chronic liver conditions worldwide, but its precise pathogenesis remains unclear. This research endeavors to elucidate the involvement and molecular mechanisms of polyribonucleotide nucleotidyltransferase 1 (PNPT1) in the progression of MAFLD.
Methods
The study employed western blot and qRT-PCR to evaluate PNPT1 levels in liver specimens from individuals diagnosed with MAFLD and in mouse models subjected to a high-fat diet. Cellular studies investigated the effects of PNPT1 on lipid metabolism, apoptosis, and mitochondrial stability in hepatocytes. Immunofluorescence was utilized to track the subcellular movement of PNPT1 under high lipid conditions. RNA immunoprecipitation and functional assays were conducted to identify interactions between PNPT1 and Mcl-1 mRNA. The role of PPARα as an upstream transcriptional regulator of PNPT1 was investigated. Recombinant adenoviral vectors were utilized to modulate PNPT1 expression in vivo.
Results
PNPT1 was found to be markedly reduced in liver tissues from MAFLD patients and HFD mice. In vitro, PNPT1 directly regulated hepatic lipid metabolism, apoptosis, and mitochondrial stability. Under conditions of elevated lipids, PNPT1 relocated from mitochondria to cytoplasm, modifying its physiological functions. RNA immunoprecipitation revealed that the KH and S1 domains of PNPT1 bind to and degrade Mcl-1 mRNA, which in turn affects mitochondrial permeability. The transcriptional regulator PPARα was identified as a significant influencer of PNPT1, impacting both its expression and subsequent cellular functions. Alterations in PNPT1 expression were directly correlated with the progression of MAFLD in mice.
Conclusions
The study confirms the pivotal function of PNPT1 in the development of MAFLD through its interactions with Mcl-1 and its regulatory effects on lipid metabolism and mitochondrial stability. These insights highlight the intricate association between PNPT1 and MAFLD, shedding light on its molecular pathways and presenting a potential new therapeutic avenue for MAFLD management.
Articles in Press
Polyribonucleotide nucleotidyltransferase 1 participates in metabolic-associated fatty liver disease pathogenesis by affecting lipid metabolism and mitochondrial homeostasis
- Abstract
Polyribonucleotide nucleotidyltransferase 1 participates in metabolic-associated fatty liver disease pathogenesis by affecting lipid metabolism and mitochondrial homeostasis
Objective
Metabolic-associated fatty liver disease (MAFLD) represents one of the most prevalent chronic liver conditions worldwide, but its precise pathogenesis remains unclear. This research endeavors to elucidate the involvement and molecular mechanisms of polyribonucleotide nucleotidyltransferase 1 (PNPT1) in the progression of MAFLD.
Methods
The study employed western blot and qRT-PCR to evaluate PNPT1 levels in liver specimens from individuals diagnosed with MAFLD and in mouse models subjected to a high-fat diet. Cellular studies investigated the effects of PNPT1 on lipid metabolism, apoptosis, and mitochondrial stability in hepatocytes. Immunofluorescence was utilized to track the subcellular movement of PNPT1 under high lipid conditions. RNA immunoprecipitation and functional assays were conducted to identify interactions between PNPT1 and Mcl-1 mRNA. The role of PPARα as an upstream transcriptional regulator of PNPT1 was investigated. Recombinant adenoviral vectors were utilized to modulate PNPT1 expression in vivo.
Results
PNPT1 was found to be markedly reduced in liver tissues from MAFLD patients and HFD mice. In vitro, PNPT1 directly regulated hepatic lipid metabolism, apoptosis, and mitochondrial stability. Under conditions of elevated lipids, PNPT1 relocated from mitochondria to cytoplasm, modifying its physiological functions. RNA immunoprecipitation revealed that the KH and S1 domains of PNPT1 bind to and degrade Mcl-1 mRNA, which in turn affects mitochondrial permeability. The transcriptional regulator PPARα was identified as a significant influencer of PNPT1, impacting both its expression and subsequent cellular functions. Alterations in PNPT1 expression were directly correlated with the progression of MAFLD in mice.
Conclusions
The study confirms the pivotal function of PNPT1 in the development of MAFLD through its interactions with Mcl-1 and its regulatory effects on lipid metabolism and mitochondrial stability. These insights highlight the intricate association between PNPT1 and MAFLD, shedding light on its molecular pathways and presenting a potential new therapeutic avenue for MAFLD management.
Save the Date

12th Helmholtz
Diabetes Conference
22-24. Sep, Munich
You are what you eat
Here is a video of Vimeo. When the iframes is activated, a connection to Vimeo is established and, if necessary, cookies from Vimeo are also used. For further information on cookies policy click here.